Introduction/Background The diagnosis of ovarian cancer tends to be late (stages III-IV). The factors that may influence the survival of stage IV patients are not clearly described, especially regarding the initial management of extra-abdominal disease and the possibility of performing surgery despite its existence. This makes it necessary to delve into their knowledge, in order to carry out a more individualized management of these patients. The purpose of this study is to analyze the prognostic factors that may have an effect on overall and disease-free survival of women diagnosed with stage IV ovarian cancer, with special interest on those related to the early management of the disease.
Methodology We performed a retrospective analysis including stage IV ovarian cancer patients, treated in Gynecologic Oncology Unit in La Paz University Hospital between 2000 and 2022 (n=110). We analyzed all risk factors that could influence the oncological outcome.
Results The correlation between disease-free survival and primary cytoreduction, in absence of residual disease, is demonstrated. No significant differences were observed in terms of overall survival when comparing patients that underwent primary cytoreduction (84 ± 11,1 months) with those who received neoadjuvant chemotherapy (90,7 ± 14,4 months). Statistically significant association was demonstrated between thoracic resection and disease-free survival (p=0,012).
Conclusion Age, performance status, initial management of the disease (primary surgery versus neoadjuvant chemotherapy) and complete cytoreduction with no residual disease, which is the greatest prognostic predictor, are the factors that have shown greater association with overall survival.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.